Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
2005/05/02 by Kerry L. Donnelly, Coleman I. Smith, Sarah Jane Schwarzenberg +5 · 3,481 citations
Medicine · Nursing · #Adipose tissue #Biology #Biopsy #Cholesterol #Chylomicron #Diet, Metabolism, and Disease #Disease #Endocrinology #Fatty Acid Research and Health #Fatty liver #Hypertriglyceridemia #Internal medicine #Lipogenesis #Lipoprotein #Liver Disease Diagnosis and Treatment #Liver biopsy #Medicine #Nonalcoholic fatty liver disease #Triglyceride #Very low-density lipoprotein
paper · open access · doi:10.1172/jci23621
published in Journal of Clinical Investigation 115(5), 1343-1351 (American Society for Clinical Investigation)
openalex publication_date 2005/05/02 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Citations
Cited by
- Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease
- De novo lipogenesis in health and disease
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men
- Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
- The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
- Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
- Mechanisms of Insulin Action and Insulin Resistance
- Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
- Query Cost Estimation in Relational Database Management System.
- PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
- Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
- Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
- SEC16B identified as a regulator of VLDL secretion and lipid accumulation in the liver
- The protein denitrosylase SCoR2 regulates lipogenesis and fat storage
- Ppp1r3b is a metabolic switch that shifts hepatic energy storage from lipid to glycogen
- P5CS-coupled proline metabolism manipulates metabolic dysfunction-associated steatotic liver disease
- Metabolite Erythritol in 24-Hour Urine Is Associated With Higher Intrahepatic Lipid Content: The Maastricht Study
- Effects of Simulated Exogenous and Endogenous Lipid Microenvironments on Cannabidiol Disposition and Cytochrome P450 2C19-Mediated Drug Interactions: New Mechanistic Insights
- Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake
- Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
- SteatoNet- Modelling steatosis identifies candidate systemic flux distribution deregulations
- Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics
- Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications
- Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- SREBP-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective
- Hepatic glucose and lipid metabolism
- Omega-3 Fatty Acids, Hepatic Lipid Metabolism, and Nonalcoholic Fatty Liver Disease
- Disordered lipid metabolism and the pathogenesis of insulin resistance. [europepmc]
- Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. [europepmc]
- Human fatty liver disease: old questions and new insights. [europepmc]
- Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. [europepmc]
- mTOR signaling in growth control and disease. [europepmc]
- Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. [europepmc]
- Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. [europepmc]
- Energy metabolism in the liver. [europepmc]
- The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. [europepmc]
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. [europepmc]
- Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. [europepmc]
- Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. [europepmc]
- Lipid droplets and liver disease: from basic biology to clinical implications. [europepmc]
- Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. [europepmc]
- Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications. [europepmc]
- Triglyceride Metabolism in the Liver. [europepmc]
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. [europepmc]
- Mechanisms of NAFLD development and therapeutic strategies. [europepmc]
- Mechanisms of Insulin Action and Insulin Resistance. [europepmc]
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. [europepmc]
- Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. [europepmc]
- Mechanisms and disease consequences of nonalcoholic fatty liver disease. [europepmc]
- Why does obesity cause diabetes? [europepmc]
- Inflammation in obesity, diabetes, and related disorders. [europepmc]
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. [europepmc]
Related